This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Evaluation
  • Claim Credit
Evolving Role of Immunotherapy in Cancer Treatment

Evolving Role of Immunotherapy in Cancer Treatment


Slide Lecture Series

Time to Complete

1.50 hours


March 1, 2019


May 22, 2020
Add to Queue

Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM

Pharmacy Credits

Pharmacists may earn 1.50 CPE Credit (0.15 CEU) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on and will not be included in your myCME CME History.

Accredited Provider

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck.

Program Description

This educational activity will explore the evolving issues, key questions and controversies associated with the use of immunotherapies for the treatment of patients with both solid tumor and hematologic malignancies. Discussion will include an overview of cancer immunobiology, types of available immunotherapy agents, current and expanding indications, evolving biomarkers and companion diagnostic testing, and management of immune-related adverse events. Patient cases will be used to highlight therapy selection as well as adverse effects and toxicity management strategies.

Intended Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of cancer patients with immunotherapies.

Educational Objectives

At the conclusion of this application-based educational activity, participants should be able to:

  • Identify the components of the human immune system and explain the mechanisms of action for using immune checkpoint inhibitors in cancer treatment.
  • Examine the role of different companion diagnostic tests and interpret PD-L1 test results as they relate to selection of immune checkpoint inhibitor therapy.
  • Analyze appropriate guidelines to guide management of common and less common immune related adverse effects from immune checkpoint inhibitors use.
  • Formulate appropriate monitoring and management strategies for patients receiving immune checkpoint inhibitors.

Conflict Of Interest Disclosure Policy

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.


Christine M. Walko, PharmD, BCOP, FCCP
Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute
Moffitt Cancer Center
Associate Professor
University of South Florida Morsani College of Medicine
Tampa, Florida

Dr. Walko discloses the following:
Honoraria received for participation in the Institute for Clinical Immuno-Oncology’s Melanoma Board: Bristol-Myers Squibb, Merck

Ragini R. Kudchadkar, MD
Associate Professor
Winship Cancer Institute of Emory University
Associate Director Hematology/Oncology Fellowship Program
Atlanta, Georgia

Dr. Kudchadkar discloses the following:
Advisory Board member: Array, Immunocore, Bristol-Myers Squibb
Research funding received: Merck

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


In order to receive credit, participants must complete the pre-assessment questions, post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For information about the accreditation of this program, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue